Cargando…

A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer

SIMPLE SUMMARY: Prior clinical studies showed modest activity for single agent everolimus and somatostatin analogues in different subtypes of thyroid cancer; the combination of everolimus and somatostatin analogue was synergistic in preclinical models of thyroid cancer. This randomized trial showed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bauman, Julie E., Chen, Zhengjia, Zhang, Chao, Ohr, James P., Ferris, Robert L., McGorisk, Gerald M., Brandt, Stephen, Srivatsa, Sumathi, Chen, Amy Y., Steuer, Conor E., Shin, Dong M., Saba, Nabil F., Khuri, Fadlo R., Owonikoko, Taofeek K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179856/ https://www.ncbi.nlm.nih.gov/pubmed/35681620 http://dx.doi.org/10.3390/cancers14112639

Ejemplares similares

Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models
por: Owonikoko, Taofeek K., et al.
Publicado: (2019)

Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials
por: Chen, Zhengjia, et al.
Publicado: (2013)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma
por: Harvey, R. Donald, et al.
Publicado: (2020)

Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data
por: Behera, Madhusmita, et al.
Publicado: (2011)

Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease
por: Machado, Márcio Carlos, et al.
Publicado: (2021)

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
por: Pakkala, Suchita, et al.
Publicado: (2020)

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion
por: Rouland, Alexia, et al.
Publicado: (2021)

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth
por: Koo, Junghui, et al.
Publicado: (2015)

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth
por: Koo, Junghui, et al.
Publicado: (2021)

Recurrent Acute Pancreatitis in the Setting of Abnormal Pancreaticobiliary Junction
por: Antonios, Kais, et al.
Publicado: (2023)

Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing
por: Oh, You-Take, et al.
Publicado: (2015)

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
por: Feun, Lynn G, et al.
Publicado: (2018)

Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer
por: Owonikoko, Taofeek K., et al.
Publicado: (2016)

Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
por: Lasolle, Hélène, et al.
Publicado: (2019)

Everolimus in combination with octreotide LAR in thymic atypical carcinoid
por: Sakane, Tadashi, et al.
Publicado: (2023)

The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo
por: Xu, Cheng-Xiong, et al.
Publicado: (2011)

Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation
por: Stelmachowska-Banaś, Maria, et al.
Publicado: (2021)

Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro
por: Graillon, Thomas, et al.
Publicado: (2017)

Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR
por: Wolf, Peter, et al.
Publicado: (2022)

Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis
por: Nazha, Bassel, et al.
Publicado: (2022)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
por: Daly, Adrian F, et al.
Publicado: (2019)

The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
por: Witek, Przemysław, et al.
Publicado: (2021)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

MON-309 Prevalence of Silent Corticotroph Adenomas in a Large Cohort of Nonfunctioning Pituitary Adenomas: Plasma Proopiomelanocortin(POMC) Levels and Response to Pasireotide LAR
por: Reyes-Vidal, Carlos, et al.
Publicado: (2020)

Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile
por: Chen, Zhengjia, et al.
Publicado: (2017)

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
por: Owonikoko, Taofeek K, et al.
Publicado: (2014)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study
por: Chéreau, Elisabeth, et al.
Publicado: (2016)

Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study
por: Benamouzig, Robert, et al.
Publicado: (2018)

In Lebanon “It Never Rains But It Pours”—How the American University of Beirut faced dangers and seized opportunities: Transforming medical education through multiple crises
por: Khuri, Fadlo R.
Publicado: (2021)

Pasireotide for the Medical Management of Feline Hypersomatotropism
por: Scudder, C.J., et al.
Publicado: (2015)

Small Molecule Bax Agonists for Cancer Therapy
por: Xin, Meiguo, et al.
Publicado: (2014)

Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States
por: Alese, Olatunji B., et al.
Publicado: (2015)

caGrid-Enabled caBIG(TM) Silver Level Compatible Head and Neck Cancer Tissue Database System
por: Wang, Haibin, et al.
Publicado: (2010)

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
por: Sheppard, Michael, et al.
Publicado: (2014)

Clinical use of pasireotide for Cushing’s disease in adults
por: Ceccato, Filippo, et al.
Publicado: (2015)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bana1to6ntldhv1vls944sdqv4